

**FOR IMMEDIATE RELEASE**

Company Name Kyowa Kirin Co., Ltd.  
Representative Abdul Mullick, President and CEO  
(Code No. 4151, Prime Market of TSE)  
Inquiries Naohiko Kubo, Executive,  
Head of Finance Department  
Media Contact: +81-3-5205-7205  
Investor Contact: +81-3-5205-7206

## Matters Concerning Controlling Shareholders

**Tokyo, Japan, March 30, 2026** - Kyowa Kirin Co., Ltd. (hereinafter, “Kyowa Kirin”) hereby provides information on “matters concerning controlling shareholders” with regard to its parent company Kirin Holdings Company, Limited. Details are as follows:

1. Names of the parent company, controlling shareholders (excluding parent company) and other associated companies and their parent companies.

(As of December 31, 2025)

| Business name                   | Relationship   | Ownership of voting rights (%) |          |       | Stock exchanges on which shares are listed   |
|---------------------------------|----------------|--------------------------------|----------|-------|--|
|                                 |                | Direct                         | Indirect | Total |  |
| Kirin Holdings Company, Limited | Parent company | 55.22                          | --       | 55.22 | - Tokyo Stock Exchange, Inc. (Prime Market)<br>- Nagoya Stock Exchange, Inc. (Premier Market)<br>- Securities Membership Corporation Sapporo Securities Exchange<br>- Securities Membership Corporation Fukuoka Stock Exchange |

2. Position of listed company within the corporate group centering on the parent company and other relationships between listed company and the parent company

- 1) Position of listed company within the corporate group centering on the parent company and other relationships between listed company and the parent company, etc.; transactional, personnel, and capital relationships with the parent company, etc. and its group companies

- Kirin Holdings Company, Limited (“Kirin Holdings”) and the Kirin Group (“Kirin Group”) have, under their long-term vision “Kirin Group Vision 2027 (KV2027)”, launched in 2019, pursued CSV management—viewing social issues as opportunities for growth—and expanded their business domains through the establishment of the Health Science business. Aligned with the vision of creating value across the fields spanning from Food & Beverages to Pharmaceuticals and becoming a global leader in CSV, the Kirin Group has advanced initiatives to address societal challenges while driving business growth. As a company operating in “Pharmaceuticals” domain—one of the business areas defined under this long-term vision—Kyowa Kirin aims to continuously deliver life-changing value that brings smiles to people facing illness, as a Japan-based global specialty pharmaceutical company.

Building on the organizational capabilities cultivated across diverse business domains through KV2027, the Kirin Group has formulated a new long-term vision, “Innovate2035!”, to ensure continued growth over the next 100 years by combining autonomous business growth with group-wide synergies. With the vision of “Vitalize the world through innovation by our people and technology, as a global leader in CSV”, the Group will advance initiatives to realize this ambition.

- Also, Kyowa Kirin’s transactional relationships with Kirin Holdings do include the lending of funds. In accordance with our investment policy, interest rates on the loans are determined through rational decisions, considering market interest rates for the loan period.

- 2) Constraints, risks and benefits from a business standpoint due to membership in the corporate group centering on the parent company, as well as impacts on management or business activities such as those affected by transactional, personnel and capital relationships, etc. with the parent company and its corporate group.

While Kyowa Kirin aims at realizing ‘the creation of life-changing value’, we consider that management resources owned by Kirin Holdings and its Group companies are beneficial to Kyowa Kirin and group companies. Kirin Group’s knowledge and know-how -particularly in production management and engineering- contribute to strengthening our business foundation. In addition, through personnel exchanges, we are also advancing the utilization of capabilities such as disease-area understanding, research know-how, and academia.

Going forward, in fulfilling our social responsibilities, we will further promote the utilization of the Kirin Group’s knowledge and know-how in areas such as environmental conservation and the stable supply of pharmaceuticals. We also believe there are opportunities to create synergies at the intersection of addressing the “various challenges faced by people confronting disease,” leveraging insights gained through our pharmaceutical business, and the “Health Science domain” that Kirin Holdings is focusing on.

As a core operating company responsible for the “Pharmaceuticals” domain, one of the Kirin Group’s business domains, Kyowa Kirin maintains managerial independence, and we recognize that there are no constraints on our business, nor any impact on our management or business activities arising from our transactional, personnel, or capital relationships with the parent company or its corporate group.

- 3) Measures to ensure a certain degree of independence from the parent company

In the Integration Agreement dated October 22, 2007, it was agreed by both companies that while observing core group management policies, Kyowa Kirin operates as an autonomous company with independence and flexibility, ensures management independence as a listed company, strives to maximize value for all shareholders and achieves consistent growth of its corporate value. Both companies follow through the Agreement.

To ensure the effectiveness of objective oversight of management and from the perspective of protecting minority shareholders, we appoint independent Outside Directors who are not likely to have conflicts of interest with general shareholders. We have also established a Nomination & Remuneration Consultative Committee, a majority of which consists of

independent Outside Directors, and have an independent Outside Director serve as Chair of the Board, while conducting evaluations of the effectiveness of the Board of Directors with the support of external organizations. The appointment and dismissal of independent Outside Directors are deliberated by the Nomination & Remuneration Consultative Committee from an objective and fair perspective and then recommended to the Board of Directors. Through these measures, we ensure independence from the parent company in the appointment of management.

### 3. Transactions with controlling shareholders and other items

Fiscal year ended December 31, 2025 (millions of yen)

| Type           | Name                            | Description of transaction | Transaction amount | Account                   | Outstanding balance |
|----------------|---------------------------------|----------------------------|--------------------|---------------------------|---------------------|
| Parent company | Kirin Holdings Company, Limited | Lending of funds *1        | 198,175            | Cash and cash equivalents | 194,108             |

\*1 The transaction amount for lending of funds represents the average balance during the fiscal year. Interest rates for loans receivable from the parent company have been reasonably determined taking into account market rates of interest according to the length of time in accordance with our own management policy.

### 4. Implementation of measures to protect minority shareholders in transactions, etc. with controlling shareholders

Transactions with the controlling shareholder, whether those be of goods and services provided by Kyowa Kirin or to Kyowa Kirin, are based on objective market information and other data, and as with ordinary transactions, rational terms are agreed, and the transaction is conducted appropriately.

In case of conducting a transaction with Kirin Holdings, the controlling shareholder, in order to address risks of conflicts of interest, when making a decision at the Board of Directors, officers who also work for the controlling shareholder, Kirin Holdings, do not participate in deliberation and resolution of such an agenda, and do not participate in our discussion and negotiations with Kirin Holdings.

With respect to a significant transaction, etc. among transactions with Kirin Holdings, Kyowa Kirin establishes the Supervisory Committee for Conflict of Interests in Transactions between Group Companies comprising all independent outside directors, which serves as an advisory body to the Board of Directors and deliberates/considers the matter and reports the Board of Directors, for the purposes of securing the fairness and rationality of such a transaction and contributing to an improvement of the corporate value of Kyowa Kirin and the protection of interest of its minority shareholders.

There were no relevant deliberations or resolutions in fiscal year 2025.

End